<code id='5EB51D6ACA'></code><style id='5EB51D6ACA'></style>
    • <acronym id='5EB51D6ACA'></acronym>
      <center id='5EB51D6ACA'><center id='5EB51D6ACA'><tfoot id='5EB51D6ACA'></tfoot></center><abbr id='5EB51D6ACA'><dir id='5EB51D6ACA'><tfoot id='5EB51D6ACA'></tfoot><noframes id='5EB51D6ACA'>

    • <optgroup id='5EB51D6ACA'><strike id='5EB51D6ACA'><sup id='5EB51D6ACA'></sup></strike><code id='5EB51D6ACA'></code></optgroup>
        1. <b id='5EB51D6ACA'><label id='5EB51D6ACA'><select id='5EB51D6ACA'><dt id='5EB51D6ACA'><span id='5EB51D6ACA'></span></dt></select></label></b><u id='5EB51D6ACA'></u>
          <i id='5EB51D6ACA'><strike id='5EB51D6ACA'><tt id='5EB51D6ACA'><pre id='5EB51D6ACA'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:3
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          Why a market frenzy over new weight loss drugs defies logic
          Why a market frenzy over new weight loss drugs defies logic

          ChristineKao/STATThere’saspecterhauntingWallStreet.Itstartedinbiotech,wherecompaniesmakingdrugsforth

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          STAT Summit: Ending the crisis of Black deaths in the U.S.

          MonicaMcLemore,aprofessorandinterimassociatedeanforequity,diversity,andinclusionattheUniversityofWas